Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and Adebelimumab as Neoadjuvant Therapy for HER2-Altered NSCLC
NCT07281209Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Pathological Complete Response at 7 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07281209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281209.